-

Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023, NY, NY:
    • Pipeline management will participate in 1x1s with investors during the conference.
  • UBS Biotechnology Private Company Virtual Symposium, September 20-21, 2023:
    • Carmine Stengone, Pipeline’s CEO, will participate in a fireside chat on Thursday, September 21, 2023, at 10:30am ET.
    • Pipeline management will also participate in 1x1s with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Contacts

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
amy@juniper-point.com

Pipeline Therapeutics


Release Versions

Contacts

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
amy@juniper-point.com

More News From Pipeline Therapeutics

Contineum Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to attend the following investor conferences during November 2024. Stife...

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. “The third quarter o...

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, Septembe...
Back to Newsroom